Posaconazole + Voriconazole
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Aspergillosis
Conditions
Aspergillosis
Trial Timeline
Jul 29, 2014 → Jan 24, 2018
NCT ID
NCT02180165About Posaconazole + Voriconazole
Posaconazole + Voriconazole is a phase 3 stage product being developed by Merck for Aspergillosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02180165. Target conditions include Aspergillosis.
What happened to similar drugs?
8 of 15 similar drugs in Aspergillosis were approved
Approved (8) Terminated (6) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02180165 | Phase 3 | Completed |
Competing Products
20 competing products in Aspergillosis